
Notice of Extraordinary General Meeting of BiBBInstruments AB (publ)

The shareholders of BibbInstruments AB (publ), 556938-9512, are hereby invited to attend an extraordinary general meeting on Friday, March 13 2026, at 3:00 p.m. at Medicon Village, Scheeletorget 1, 223 81 Lund, Sweden, in the "Utsikten" room, floor 4, building 405.

Right to participate and registration

Shareholders who wish to participate in the general meeting must

- be listed in the share register maintained by Euroclear Sweden AB on March 5, 2026, and
- register with the company no later than on March 9, 2026 by email to info@bibbinstruments.com. Registration can also be made by telephone to 0708-99 94 86 or in writing to BiBBInstruments AB, Medicon Village, 223 81 Lund. The registration must include your full name, personal or organization number, shareholding, address, daytime telephone number and, where applicable, information about representatives or assistants (maximum 2). Where applicable, the registration should be accompanied by powers of attorney, registration certificates and other authorization documents.

Nominee-registered shares

In order to be entitled to participate in the meeting, persons who have had their shares registered in the name of a nominee must, through the nominee, have the shares registered in their own name so that they are registered in the share register maintained by Euroclear Sweden AB on the record date of March 5, 2026. Such registration may be temporary (known as voting rights registration).

Shareholders who wish to register their shares in their own name must, in accordance with the procedures of the respective nominee, request that the nominee make such voting rights registration. Voting rights registration requested by shareholders in such time that the registration has been made by the relevant nominee no later than March 9, 2026, will be taken into account in the preparation of the share register.

Proxies, etc.

If shareholders are to be represented by a proxy, the proxy must bring a written, dated, and signed proxy form to the meeting. The proxy form may not be older than one year, unless a longer period of validity (but no longer than five years) has been specified in the proxy form. If the power of attorney has been issued by a legal entity, the proxy must also bring a current certificate of registration or equivalent authorization document for the legal entity. To facilitate admission, a copy of the power of attorney and other authorization documents should be enclosed with the notice of attendance at the meeting. Power of attorney forms are available on the company's website, www.bibbinstruments.com, and will be sent by mail to shareholders who contact the company and provide their address.

Number of shares and votes

The number of outstanding shares and votes in the company at the time of this notice is 40,739,302. The company does not hold any of its own shares.

Proposed agenda

1. Opening of the meeting.
2. Election of chairman.
3. Preparation and approval of the voting list.
4. Election of one or two persons to verify the minutes.
5. Verification that the meeting has been duly convened.
6. Approval of the agenda.
7. The Board's proposal for a resolution to amend the Articles of Association.
8. The Board of Directors' proposal for a resolution authorizing the Board of Directors to decide on issues.
9. The meeting is adjourned.

Summary of proposed resolutions:

§ 2. Election of Chairman

Fredrik Lindblad has been proposed as Chairman of the Meeting.

§ 7. The Board's proposal for a resolution on amendments to the Articles of Association

In order to enable the preferential issue of shares proposed for approval under item 8 on the agenda for the meeting (the "Preferential Issue"), the Board of Directors proposes that the meeting resolve to amend the company's Articles of Association by adopting new limits for the share capital and the number of shares. The Board has prepared three proposals for amendments to the Articles of Association, Alternative A, Alternative B, and Alternative C. Only one set of Articles of Association is intended to be registered with the Swedish Companies Registration Office. Which set of Articles of Association is ultimately registered will depend on the final transaction structure and how many shares are issued, subscribed for, and paid for in the Rights Issue.

It is proposed that the Board of Directors be authorized to register the company's new Articles of Association in accordance with one of Alternative A, Alternative B, and Alternative C, based on what the Board of Directors, after considering the final terms and conditions and the outcome of the Rights Issue, deems most appropriate. The Meeting is thus proposed to decide on all alternatives, but only one of the alternatives will ultimately be registered with the Swedish Companies Registration Office. The Board may also find it most appropriate not to register any Articles of Association at all.

Amendments to the Articles of Association according to Alternative A

§4 Share capital

Current wording

The share capital shall be no less than SEK 2,482,000 and no more than SEK 9,928,000.

Proposed wording

The share capital shall be no less than SEK 4,964,000 and no more than SEK 19,856,000.

§5 Number of shares

Current wording

The number of shares shall be no less than 29,200,000 and no more than 116,800,000.

Proposed wording

The number of shares shall be no less than 58,400,000 and no more than 233,600,000.

Amendments to the Articles of Association according to Alternative B

§4 Share capital

Current wording

The share capital shall be no less than SEK 2,482,000 and no more than SEK 9,928,000.

Proposed wording

The share capital shall be no less than SEK 9,928,000 and no more than SEK 39,712,000.

§5 Number of shares

Current wording

The number of shares shall be no less than 29,200,000 and no more than 116,800,000.

Proposed wording

The number of shares shall be no less than 116,800,000 and no more than 467,200,000.

Amendments to the Articles of Association according to Alternative C

§4 Share capital

Current wording

The share capital shall be no less than SEK 2,482,000 and no more than SEK 9,928,000.

Proposed wording

The share capital shall be no less than SEK 19,856,000 and no more than SEK 79,424,000.

§5 Number of shares

Current wording

The number of shares shall be no less than 29,200,000 and no more than 116,800,000.

Proposed wording

The number of shares shall be no less than 233,600,000 and no more than 934,400,000.

The resolution of the Meeting in accordance with the Board's proposal under Alternatives A-C above shall be adopted as a joint resolution.

The resolution to amend the Articles of Association is conditional upon the Extraordinary General Meeting resolving to approve the authorization in accordance with the Board of Directors' proposal under item 8 on the agenda for the Meeting.

§ 8 The Board of Directors' proposal for a resolution to authorize the Board of Directors to decide on issues

The Board of Directors proposes that the Extraordinary General Meeting resolve to authorize the Board of Directors, during the period until the next Annual General Meeting, to decide on the issue of a maximum number of shares, convertibles and/or warrants entitling the holder to subscribe for, or involving the issue of, a maximum number of shares within the limits of the Articles of Association in force at any given time, with or without deviation from the shareholders' preferential rights. The authorization may be exercised on one or more occasions, and the Board of Directors shall have the right to decide on the detailed terms and conditions of the issue on each individual occasion. In addition to cash payment, payment may also be made in kind or by set-off, or otherwise on certain terms and conditions.

In order to ensure that the company's current shareholders are not disadvantaged in relation to the external investor(s) who may subscribe for shares in the company, the Board of Directors considers it appropriate that issues with deviation from the shareholders' preferential rights shall be made at the subscription price assessed by the Board of Directors in accordance with market conditions, subject to a market-based issue discount where applicable.

For a valid decision, it must be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the Annual General Meeting.

Other

Copies of proxy forms, complete proposals for resolutions, and other documents that must be made available in accordance with the Swedish Companies Act are available at the company's offices at Medicon Village, 223 81 Lund, Sweden, and on the Company's website, www.bibbinstruments.com, no later than two weeks before the meeting. All documents as above will be sent to shareholders who request them and provide their email or postal address.

Shareholders are reminded of their right to request information from the Board of Directors and the CEO at the Extraordinary General Meeting in accordance with Chapter 7, Section 32 of the Swedish Companies Act.

Handling of personal data

For information on how personal data is processed in connection with the general meeting, please refer to the privacy policy available on Euroclear Sweden AB's website:
www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf

* * *

Lund, February 2026
BibbInstruments AB (publ)
The Board

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

About BiBB

BiBBInstruments AB is a cancer diagnostics company that develops and commercializes EndoDrill®, the world's first series of powered endoscopic biopsy instruments with market clearance in the United States and CE marking in Europe. EndoDrill® is designed to collect core tissue samples (core needle biopsies, CNB) with high diagnostic accuracy and aims to improve the diagnosis of cancer in, among others, the stomach, pancreas, liver, lungs and urinary bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments in modern endoscopy. BiBB received market clearance (510(k)) from the U.S. Food and Drug Administration (FDA) for its first instrument, EndoDrill® GI, in 2023 and obtained CE marking under the EU Medical Device Regulation (MDR) in 2024 for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. The U.S. launch of EndoDrill® GI was initiated in the autumn of 2025 in collaboration with TaeWoong Medical USA. The EndoDrill® system consists of sterile single-use instruments and a proprietary drive system. BiBB was founded in 2013 by Dr Charles Walther, a cancer researcher at Lund University and a senior consultant in clinical pathology at Skåne University Hospital. The company is headquartered at Medicon Village in Lund, Sweden, and its shares are traded on Spotlight Stock Market (ticker: BIBB).